Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Nexium, Nexium 24HR (OTC) (1)

Amphetamine (1) · Analgesic (2) · Opioid (2) · Prodrug (1) · Research material (1) · Stimulant (1) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:Proton_pump_inhibitors|Proton pump inhibitor (PPI)]] (1)

Monoamine releasing agent (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · '"`UNIQ--vote-000008E1-QINU`"' Like omeprazole, it is an acid-activated prodrug that covalently and irreversibly binds the H+/K+ ATPase. CYP2C19 PGx remains clinically relevant for both'"`UNIQ--ref-000008E2-QINU`"'. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000008E3-QINU`"', '"`UNIQ--vote-000008E4-QINU`"', '"`UNIQ--vote-000008E5-QINU`"', '"`UNIQ--vote-000008E6-QINU`"', '"`UNIQ--vote-000008E7-QINU`"' (1)

None (2) · 20-40 mg PO once daily, 30-60 minutes before breakfast (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (2) · 20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison (1)

None (2) · IV (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (2) · 30–60 min (PO) (1) · Acid suppression within hours; full effect after 3-5 days of dosing (1)

None (2) · 24-72 hours per dose (irreversible enzyme binding) (1) · 4–6 hours (1)

None (2) · 2.5–3 hours (1) · ~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover'"`UNIQ--ref-000008E8-QINU`"' (1)

None (2) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"' (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Widely used in obstetric reflux; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · OTC (20 mg, 14-day course) and [[USLegal:Prescription only|Rx-only]] (higher and longer durations) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)